Keryx Biopharmaceuticals' Zerenex(TM) Data Selected For Poster Presentation At The AMCP's 26th Annual Meeting And Expo

NEW YORK, March 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that data highlighting the potential pharmacoeconomic benefit of Zerenex™ (ferric citrate coordination complex), the Company's drug candidate for the treatment of hyperphosphatemia in dialysis patients, has been selected for poster presentation during the upcoming Academy of Managed Care Pharmacy's (AMCP) 26 th Annual Meeting and Expo, being held April 1-4, 2014, at the Tampa Convention Center in Tampa, Florida.  

The poster, entitled, "Phosphorus Binding with Ferric Citrate Reduces Managed Care Costs Through Reduced Use of IV Iron and Erythropoiesis-Stimulating Agents (ESAs)," is scheduled to be presented in the poster session on Thursday, April 3, 2014, from 11:30am-2:30 pm, in the West and Central Hall of the convention center. 

The abstract (Abstract No. N1EM) can be viewed online at the AMCP website: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=17843.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex™ (ferric citrate coordination complex), an oral, ferric iron-based compound. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment agreement with the FDA. Keryx's New Drug Application, submitted to the FDA in 2013, is currently under review and has an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. Keryx has recently submitted a Marketing Authorization Application filing to the European Medicines Agency. Zerenex has also completed a Phase 2 study in the U.S. for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd., received marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease on January 17, 2014. Keryx is headquartered in New York City.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)